Cited 596 times in
A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권혁문 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 남정모 | - |
dc.contributor.author | 신동호 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 고영국 | - |
dc.date.accessioned | 2014-12-19T17:16:59Z | - |
dc.date.available | 2014-12-19T17:16:59Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0735-1097 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/91120 | - |
dc.description.abstract | OBJECTIVES: The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. BACKGROUND: There have been few published reports of prospective randomized clinical studies comparing the safety and efficacy of shorter duration DAPT after DES implantation. METHODS: We randomly assigned 2,117 patients with coronary artery stenosis into 2 groups according to DAPT duration and stent type: 3-month DAPT following Endeavor zotarolimus-eluting stent (E-ZES) implantation (E-ZES+3-month DAPT, n=1,059) versus 12-month DAPT following the other DES implantation (standard therapy, n=1,058). We hypothesized that the E-ZES+3-month DAPT would be noninferior to the standard therapy for the primary composite endpoint (cardiovascular death, myocardial infarction, stent thrombosis, target\vessel revascularization, or bleeding) at 1 year. RESULTS: The primary endpoint occurred in 40 (4.7%) patients assigned to E-ZES+3-month DAPT compared with 41 (4.7%) patients assigned to the standard therapy (difference: 0.0%; 95% confidence interval [CI]: -2.5 to 2.5; p=0.84; p<0.001 for noninferiority). The composite rates of any death, myocardial infarction, or stent thrombosis were 0.8% and 1.3%, respectively (difference: -0.5%; 95% CI: -1.5 to 0.5; p=0.48). The rates of stent thrombosis were 0.2% and 0.3%, respectively (difference: -0.1%; 95% CI: -0.5 to 0.3; p=0.65) without its further occurrence after cessation of clopidogrel in the E-ZES+3-month DAPT group. The rates of target vessel revascularization were 3.9% and 3.7%, respectively (difference: 0.2%; 95% CI: -2.3 to 2.6; p=0.70). CONCLUSIONS: E-ZES+3-month DAPT was noninferior to the standard therapy with respect to the occurrence of the primary endpoint. (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation [RESET]; NCT01145079). | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1340~1348 | - |
dc.relation.isPartOf | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Preventive Medicine (예방의학) | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Dong-Ho Shin | - |
dc.contributor.googleauthor | Chung-Mo Nam | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Tae-Soo Kang | - |
dc.contributor.googleauthor | Byoung-Eun Park | - |
dc.contributor.googleauthor | Woong-Chol Kang | - |
dc.contributor.googleauthor | Seung-Hwan Lee | - |
dc.contributor.googleauthor | Jung-Han Yoon | - |
dc.contributor.googleauthor | Bum-Kee Hong | - |
dc.contributor.googleauthor | Hyuck-Moon Kwon | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.identifier.doi | 10.1016/j.jacc.2012.06.043 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00260 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A01264 | - |
dc.contributor.localId | A02097 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A00127 | - |
dc.relation.journalcode | J01770 | - |
dc.identifier.eissn | 1558-3597 | - |
dc.identifier.pmid | antiplatelet therapy ; coronary artery disease ; drug-eluting stents | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S073510971203029X | - |
dc.subject.keyword | antiplatelet therapy | - |
dc.subject.keyword | coronary artery disease | - |
dc.subject.keyword | drug-eluting stents | - |
dc.contributor.alternativeName | Kwon, Hyuck Moon | - |
dc.contributor.alternativeName | Kim, Byeong Keuk | - |
dc.contributor.alternativeName | Kim, Jung Sun | - |
dc.contributor.alternativeName | Nam, Jung Mo | - |
dc.contributor.alternativeName | Shin, Dong Ho | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.alternativeName | Choi, Dong Hoon | - |
dc.contributor.alternativeName | Hong, Myeong Ki | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | Kwon, Hyuck Moon | - |
dc.contributor.affiliatedAuthor | Kim, Byeong Keuk | - |
dc.contributor.affiliatedAuthor | Kim, Jung Sun | - |
dc.contributor.affiliatedAuthor | Nam, Jung Mo | - |
dc.contributor.affiliatedAuthor | Shin, Dong Ho | - |
dc.contributor.affiliatedAuthor | Jang, Yang Soo | - |
dc.contributor.affiliatedAuthor | Choi, Dong Hoon | - |
dc.contributor.affiliatedAuthor | Hong, Myeong Ki | - |
dc.contributor.affiliatedAuthor | Ko, Young Guk | - |
dc.citation.volume | 60 | - |
dc.citation.number | 15 | - |
dc.citation.startPage | 1340 | - |
dc.citation.endPage | 1348 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol.60(15) : 1340-1348, 2012 | - |
dc.identifier.rimsid | 33927 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.